Clinical Trials Logo

Transverse Myelitis clinical trials

View clinical trials related to Transverse Myelitis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01446575 Terminated - Transverse Myelitis Clinical Trials

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis

Start date: July 2012
Phase: Phase 4
Study type: Interventional

Transverse myelitis is an inflammatory disorder of the spinal cord that leads to disabilities of gait. Dalfampridine, a sustained-release potassium channel blocker that has been shown to be effective in improving gait and other neurologic functions in multiple sclerosis. Dalfampridine has the potential to improve gait and neurologic function in patients with transverse myelitis as this rare disorder shares a similar pathogenic process with multiple sclerosis. The investigators propose a clinical trial to test the efficacy of dalfampridine in this particular cohort of patients. The clinical trial that the investigators propose to conduct will focus on monophasic idiopathic Transverse Myelitis (TM) and will evaluate the efficacy of dalfampridine in primary neurologic outcome, 25-foot timed walk, and several secondary outcomes including valid behavioral and neurophysiological measures. To better understand the mechanisms underlying the proposed behavioral gains, the investigators will use Transcranial Magnetic Stimulation as the neurophysiologic measure to identify changes in corticomotor excitability in the spinal cord.